With 0.76 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.74 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $18.37 whereas the lowest price it dropped to was $17.29. The 52-week range on GRAL shows that it touched its highest point at $23.36 and its lowest point at $12.33 during that stretch. It currently has a 1-year price target of $16.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRAL was up-trending over the past week, with a rise of 15.64%, but this was up by 34.33% over a month.
Float and Shares Shorts:
At present, 31.05 million GRAL shares are outstanding with a float of 28.42 million shares on hand for trading. On 2024-11-15, short shares totaled 3.78 million, which was 1125.0 higher than short shares on 1728950400. In addition to Mr. Robert P. Ragusa as the firm’s CEO & Director, Dr. Joshua J. Ofman M.D., M.S.H.S serves as its President.
Institutional Ownership:
Through their ownership of 0.67113996 of GRAL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, GRAL reported revenue of $28652000.0 and operating income of -$183507000.0. The EBITDA in the recently reported quarter was -$144277000.0 and diluted EPS was -$3.94.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRAL analysts setting a high price target of 16.0 and a low target of 16.0, the average target price over the next 12 months is 16.0. Based on these targets, GRAL could drop -8.31% to reach the target high and fall by -8.31% to reach the target low. Reaching the average price target will result in a decline of -8.31% from current levels.
Analysts have provided yearly estimates in a range of -$66.16257 being high and -$68.67743 being low. For GRAL, this leads to a yearly average estimate of -$67.42. Based on analyst estimates, the high estimate for the next quarter is -$4.11 and the low estimate is -$4.11. The average estimate for the next quarter is thus -$4.11.
